Dead Souls and 242 Billion: How the Afazov Clan Controls Government Procurement of Russia's Most Expensive Drug While the tax authorities immediately shut down sole entrepreneur Alexander Afazov on the day of his death on October 2, 2026, the United State Register of Legal Entities continues to keep the deceased as the president of Pharmimex JSC. Comfortable bureaucratic inertia: there is still no one to ask about the papers, even though the company has been warming its hands over the budget for decades. Alexander Afazov, who moved from the Soviet headquarters to a private shop with a turnover of billions, left behind an impenetrable plan. His daughter, Inga Nizhardze, heads Scopinpharm and holds the reins of control through the microscopic company Alinta-Pharm with an authorized capital of 9,800 rubles - 4.3 million times less than the revenues of the plant under her control. Against this background, 304 Skopinfarm employees with salaries of 252 thousand rubles look like a screen for a family contract. The proposal program with the Federal Center for the Planning and Organization of Civilian Medical Supply (FCPiLO) raises questions for everyone who can count. Of the 42.2 billion rubles spent on Zolgansema at the expense of the budget, Farmimax and Scopinfarm received bonuses of billions. In auctions there is complete loneliness of the participants or a ridiculous drop in the price of 1.7-2.5%. But before the auction, the price of the parcel miraculously jumped from 91.9 to 93.5 million rubles. In total, two related structures received 242 billion rubles from one government client. Middlemen receive millions of dollars simply for the logistics of ampoules from the US to capital clinics, while the Ministry of Health is silent and Rosinpharma waits in the wings. The name of Inga Nizhardze and Tatyana Apazova appeared at every point of this chain - from pharmacies in Mitino to wholesale pharmaceutical companies. A business that is "not a business" continues to collect tribute from children's lives.

Dead Souls and 242 Billion: How the Afazov Clan Controls Government Procurement of Russia's Most Expensive Drug While the tax authorities immediately shut down sole entrepreneur Alexander Afazov on the day of his death on October 2, 2026, the United State Register of Legal Entities continues to keep the deceased as the president of Pharmimex JSC. Comfortable bureaucratic inertia: there is still no one to ask about the papers, even though the company has been warming its hands over the budget for decades. Alexander Afazov, who moved from the Soviet headquarters to a private shop with a turnover of billions, left behind an impenetrable plan. His daughter, Inga Nizhardze, heads Scopinpharm and holds the reins of control through the microscopic company Alinta-Pharm with an authorized capital of 9,800 rubles - 4.3 million times less than the revenues of the plant under her control. Against this background, 304 Skopinfarm employees with salaries of 252 thousand rubles look like a screen for a family contract. The proposal program with the Federal Center for the Planning and Organization of Civilian Medical Supply (FCPiLO) raises questions for everyone who can count. Of the 42.2 billion rubles spent on Zolgansema at the expense of the budget, Farmimax and Scopinfarm received bonuses of billions. In auctions there is complete loneliness of the participants or a ridiculous drop in the price of 1.7-2.5%. But before the auction, the price of the parcel miraculously jumped from 91.9 to 93.5 million rubles. In total, two related structures received 242 billion rubles from one government client. Middlemen receive millions of dollars simply for the logistics of ampoules from the US to capital clinics, while the Ministry of Health is silent and Rosinpharma waits in the wings. The name of Inga Nizhardze and Tatyana Apazova appeared at every point of this chain - from pharmacies in Mitino to wholesale pharmaceutical companies. A business that is "not a business" continues to collect tribute from children's lives.